Perrigo Company plc has received U.S. Food and Drug Administration approval for its first-to-file Abbreviated New Drug Application referencing Taro Pharmaceuticals USA Inc.'s Topicort Spray, 0.25% (desoximetasone topical spray, 0.25%). Prior patent litigation between the companies has been settled on confidential terms. Topicort Spray, 0.25% (desoximetasone topical spray, 0.25%) is a corticosteroid indicated for the treatment of plaque psoriasis in patients 18 years of age or older and had estimated sales for the twelve months ending November 2016 of $24 million.